半张力症作为神经性精神病患者的副作用:以临床为例

Q4 Medicine
Sheila Cruz Bailén, Fermín González Higueras, Mirta Olga Solís
{"title":"半张力症作为神经性精神病患者的副作用:以临床为例","authors":"Sheila Cruz Bailén,&nbsp;Fermín González Higueras,&nbsp;Mirta Olga Solís","doi":"10.1016/j.psiq.2024.100558","DOIUrl":null,"url":null,"abstract":"<div><div>Tardive dyskinesias are persistent abnormal movements, occasionally irreversible, that appear during prolonged use of neuroleptics. It is presented the case of a 21-year-old male under follow-up in Mental Health since 2013 with a diagnosis of schizophrenia and on neuroleptic treatment since the age of 13. Two years ago he began to present orolingual dyskinesia and steppage gait; medication was reduced, but no clinical improvement was found. The patient was being treated with aripiprazole and paliperidone, which was reduced due to the appearance of extrapyramidalism, and he was switched to monotherapy with paliperidone depot. In the last months, lurasidone was introduced and depot was discontinued, persisting with gait and speech difficulties. Finally, a diagnosis of hemidystonia secondary to drugs was made. No improvement has been found with muscle relaxants or any of the drugs used and local botulinum toxin and deep brain stimulation have been proposed. The adverse effects of neuroleptics can be expressed with a wide variety of clinical manifestations and are difficult to reverse. In conclusion, prevention by monitoring symptoms every 6–12 months and assessing the risk–benefit of these drugs is important.</div></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"31 ","pages":"Article 100558"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hemidistonía como efecto adverso de neurolépticos: A propósito de un caso clínico\",\"authors\":\"Sheila Cruz Bailén,&nbsp;Fermín González Higueras,&nbsp;Mirta Olga Solís\",\"doi\":\"10.1016/j.psiq.2024.100558\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Tardive dyskinesias are persistent abnormal movements, occasionally irreversible, that appear during prolonged use of neuroleptics. It is presented the case of a 21-year-old male under follow-up in Mental Health since 2013 with a diagnosis of schizophrenia and on neuroleptic treatment since the age of 13. Two years ago he began to present orolingual dyskinesia and steppage gait; medication was reduced, but no clinical improvement was found. The patient was being treated with aripiprazole and paliperidone, which was reduced due to the appearance of extrapyramidalism, and he was switched to monotherapy with paliperidone depot. In the last months, lurasidone was introduced and depot was discontinued, persisting with gait and speech difficulties. Finally, a diagnosis of hemidystonia secondary to drugs was made. No improvement has been found with muscle relaxants or any of the drugs used and local botulinum toxin and deep brain stimulation have been proposed. The adverse effects of neuroleptics can be expressed with a wide variety of clinical manifestations and are difficult to reverse. In conclusion, prevention by monitoring symptoms every 6–12 months and assessing the risk–benefit of these drugs is important.</div></div>\",\"PeriodicalId\":39337,\"journal\":{\"name\":\"Psiquiatria Biologica\",\"volume\":\"31 \",\"pages\":\"Article 100558\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psiquiatria Biologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1134593424001180\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psiquiatria Biologica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1134593424001180","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

迟发性运动障碍是在长期使用抗精神病药期间出现的持续性异常运动,有时是不可逆的。本文介绍了一名21岁男性自2013年以来在精神卫生部门接受随访的病例,他被诊断为精神分裂症,自13岁起接受抗精神病药物治疗。两年前,他开始出现多语运动障碍和步进步态;减少了药物治疗,但没有发现临床改善。患者正在接受阿立哌唑和帕利哌酮的治疗,由于锥体外系症的出现而减少了剂量,并改用帕利哌酮储库单药治疗。在最后几个月,卢拉西酮被引入并停药,持续存在步态和语言困难。最后诊断为药物引起的半肌张力障碍。肌肉松弛剂或任何药物都没有改善,局部肉毒杆菌毒素和深部脑刺激已被提出。抗精神病药的不良反应可以表现为各种各样的临床表现,并且难以逆转。总之,通过每6-12 个月监测症状并评估这些药物的风险-收益进行预防是重要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hemidistonía como efecto adverso de neurolépticos: A propósito de un caso clínico
Tardive dyskinesias are persistent abnormal movements, occasionally irreversible, that appear during prolonged use of neuroleptics. It is presented the case of a 21-year-old male under follow-up in Mental Health since 2013 with a diagnosis of schizophrenia and on neuroleptic treatment since the age of 13. Two years ago he began to present orolingual dyskinesia and steppage gait; medication was reduced, but no clinical improvement was found. The patient was being treated with aripiprazole and paliperidone, which was reduced due to the appearance of extrapyramidalism, and he was switched to monotherapy with paliperidone depot. In the last months, lurasidone was introduced and depot was discontinued, persisting with gait and speech difficulties. Finally, a diagnosis of hemidystonia secondary to drugs was made. No improvement has been found with muscle relaxants or any of the drugs used and local botulinum toxin and deep brain stimulation have been proposed. The adverse effects of neuroleptics can be expressed with a wide variety of clinical manifestations and are difficult to reverse. In conclusion, prevention by monitoring symptoms every 6–12 months and assessing the risk–benefit of these drugs is important.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Psiquiatria Biologica
Psiquiatria Biologica Medicine-Psychiatry and Mental Health
CiteScore
0.40
自引率
0.00%
发文量
13
期刊介绍: Es la Publicación Oficial de la Sociedad Española de Psiquiatría Biológica. Los recientes avances en el conocimiento de la bioquímica y de la fisiología cerebrales y el progreso en general en el campo de las neurociencias han abierto el camino al desarrollo de la psiquiatría biológica, fundada sobre bases anatomofisiológicas, más sólidas y científicas que la psiquiatría tradicional.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信